Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05509933 · ClinicalTrials.gov registry record · Phase 3
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
A Phase 3 study of Engraftment Syndrome, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT05509933 is a Phase 3 study of Engraftment Syndrome that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 110 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05509933, a Phase 3 study of Engraftment Syndrome, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Conditions Studied
Interventions
- DRUG Budesonide
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05509933
The ClinicalTrials.gov registry entry for NCT05509933 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Engraftment Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Budesonide is the first listed.
NCT05509933 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05509933 about?
NCT05509933 is a clinical study titled "Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation". The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
What is the current status of trial NCT05509933?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2022-11-09. Estimated completion is 2026-12-30.
What conditions does trial NCT05509933 study?
This clinical trial studies the following conditions: Engraftment Syndrome.
What interventions are being tested in trial NCT05509933?
The interventions under investigation include: Budesonide (DRUG).
Who is sponsoring clinical trial NCT05509933?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05509933 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.